Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Nuvectis Pharma, Inc. NVCT
$15.90
+$0.86 (5.40%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
237625248.00000000
-
week52high
20.92
-
week52low
6.21
-
Revenue
149000
-
P/E TTM
-10
-
Beta
0.00000000
-
EPS
-1.55000000
-
Last Dividend
0.00000000
-
Next Earnings Date
07 мар 2023 г. в 13:00
Описание компании
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Ladenburg Thalmann | Buy | 13 июл 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 10 мая 2022 г. |
| HC Wainwright & Co. | Buy | 02 мар 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Shemesh Shay | A | 1360865 | 115000 | 12 янв 2023 г. |
| BENTSUR RON | A | 3225459 | 210000 | 12 янв 2023 г. |
| Poradosu Enrique | A | 1373319 | 115000 | 12 янв 2023 г. |
| Shemesh Shay | A | 1245865 | 500 | 21 дек 2022 г. |
| BENTSUR RON | A | 3015459 | 150 | 30 ноя 2022 г. |
| BENTSUR RON | A | 3015309 | 150 | 29 ноя 2022 г. |
| BENTSUR RON | A | 3015159 | 150 | 28 ноя 2022 г. |
| BENTSUR RON | A | 3015009 | 150 | 25 ноя 2022 г. |
| BENTSUR RON | A | 3014859 | 500 | 18 ноя 2022 г. |
| BENTSUR RON | A | 3014359 | 250 | 17 ноя 2022 г. |
Новостная лента
These Are the 10 Best-Performing IPOs in 2022 Through October
24/7 Wall Street
16 ноя 2022 г. в 21:21
The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.
Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
GlobeNewsWire
03 окт 2022 г. в 16:30
FORT LEE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company's management team will participate at the Roth Inaugural Healthcare Opportunities Conference.
Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences
GlobeNewsWire
07 сент 2022 г. в 08:30
FORT LEE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences in September.
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
GlobeNewsWire
20 мая 2022 г. в 10:21
FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference.
3 Moonshot Stocks Insiders Are Buying. What Do They Know?
InvestorPlace
25 февр 2022 г. в 10:33
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.